Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

Is Tamsulosin Linked to Dementia in the Elderly?

Frankel JK, Duan Y, Albertsen PC.

Curr Urol Rep. 2018 Jul 3;19(9):69. doi: 10.1007/s11934-018-0821-0. Review.

PMID:
29971698
2.

New alpha blockers to treat male lower urinary tract symptoms.

Hwang EC, Gandhi S, Jung JH.

Curr Opin Urol. 2018 May;28(3):273-276. doi: 10.1097/MOU.0000000000000488.

PMID:
29613909
3.

Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.

Sridharan K, Sivaramakrishnan G.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):291-307. doi: 10.1080/17512433.2018.1424537. Epub 2018 Jan 19. Review.

PMID:
29334287
4.

Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.

Duan Y, Grady JJ, Albertsen PC, Helen Wu Z.

Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):340-348. doi: 10.1002/pds.4361. Epub 2018 Jan 9.

PMID:
29316005
5.

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P.

Cochrane Database Syst Rev. 2017 Nov 22;11:CD012615. doi: 10.1002/14651858.CD012615.pub2. Review.

PMID:
29161773
6.

[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].

Bensalah N, Garcia S, Rose FX, Bedouch P, Conort O, Juste M, Roubille R, Allenet B, Tod M, Charpiat B.

Prog Urol. 2017 Apr;27(5):275-282. doi: 10.1016/j.purol.2017.02.003. Epub 2017 Mar 30. Review. French.

PMID:
28365198
7.

Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review.

Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D.

Biomed Pharmacother. 2016 Oct;83:1141-1145. doi: 10.1016/j.biopha.2016.08.021. Epub 2016 Aug 20. Review.

PMID:
27551761
8.

Risk factors for intraoperative floppy iris syndrome: a prospective study.

Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P; Medscape.

Eye (Lond). 2016 Aug;30(8):1039-44. doi: 10.1038/eye.2016.122. Epub 2016 Jul 1.

9.

Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.

He F, Man LB, Li GZ, Liu N.

Drug Des Devel Ther. 2016 May 26;10:1783-93. doi: 10.2147/DDDT.S103195. eCollection 2016.

10.

Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia.

Akkoc A, Aydin C, Topaktas R, Kartalmis M, Altin S, Isen K, Metin A.

Int Braz J Urol. 2016 May-Jun;42(3):578-84. doi: 10.1590/S1677-5538.IBJU.2015.0256.

11.

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK.

Indian J Pharmacol. 2016 Mar-Apr;48(2):134-40. doi: 10.4103/0253-7613.178825.

12.

Modified corneal incisions in intraoperative floppy iris syndrome (IFIS)-prone patients.

Armarnik S, Mimouni M, Rosen E, Assia EI, Segev F.

Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):123-7. doi: 10.1007/s00417-015-3188-7. Epub 2015 Nov 9.

PMID:
26553196
13.

The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study.

Welk B, McArthur E, Fraser LA, Hayward J, Dixon S, Hwang YJ, Ordon M.

BMJ. 2015 Oct 26;351:h5398. doi: 10.1136/bmj.h5398.

14.

Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.

Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP.

PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. eCollection 2015. Review.

15.

Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.

Liu S, Yu Y, Gao Y, Yang X, Pang Z.

Urolithiasis. 2016 Apr;44(2):185-90. doi: 10.1007/s00240-015-0810-4. Epub 2015 Aug 5.

PMID:
26242466
16.

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.

Yuan JQ, Mao C, Wong SY, Yang ZY, Fu XH, Dai XY, Tang JL.

Medicine (Baltimore). 2015 Jul;94(27):e974. doi: 10.1097/MD.0000000000000974.

17.

Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study.

Park SG, Chung BH, Lee SW, Park JK, Park K, Cheon J, Lee KS, Kim HJ, Seong DH, Oh SJ, Kim SW, Lee JY, Choo SH, Choi JB.

Int Neurourol J. 2015 Jun;19(2):107-12. doi: 10.5213/inj.2015.19.2.107. Epub 2015 Jun 29.

18.

Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).

Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, Wehling M.

Age Ageing. 2015 Sep;44(5):745-55. doi: 10.1093/ageing/afv077. Epub 2015 Jun 23. Review.

19.

The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo.

Kwon JK, Cho KS, Oh CK, Kang DH, Lee H, Ham WS, Choi YD, Lee JY.

BMC Urol. 2015 Jun 24;15:55. doi: 10.1186/s12894-015-0050-5. Review.

20.

Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study.

El Said NO, El Wakeel L, Kamal KM, Morad Ael R.

Pharmacotherapy. 2015 May;35(5):470-6. doi: 10.1002/phar.1593.

PMID:
26011140

Supplemental Content

Loading ...
Support Center